Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium 177 DOTA HYNIC panPSMA - Telix Pharmaceuticals

Next Previous
Drug Profile

Lutetium 177 DOTA HYNIC panPSMA - Telix Pharmaceuticals

Alternative Names: 177Lu-DOTA-HYNIC-panPSMA; [177Lu]Lu-PSMA; Lutetium-177-DOTA-HYNIC-panPSMA - Telix Pharmaceuticals; TLX597 Tx

Latest Information Update: 11 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Telix Pharmaceuticals
  • Class Antineoplastics; Radioisotopes; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 30 Apr 2026 Telix Pharmaceuticals plans a phase II OPTIMAL-E trial for Prostate cancer (mHSPC)
  • 07 Apr 2026 Pharmacokinetics data from a preclinical studies in Prostate cancer released by Telix Pharmaceuticals
  • 16 Jun 2025 Phase-II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Second line therapy or greater) in Australia (IV) (ACTRN12625000971437)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top